Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza raka jelita grubego (typu MSS) na podstawie biopsji
- •Przerzuty do wątroby, które można usunąć operacyjnie
- •Wiek co najmniej 18 lat
- •Dobry stan zdrowia ogólny (zdolność do tolerowania leczenia)
- •Dla kobiet i mężczyzn w wieku rozrodczym: zgoda na stosowanie antykoncepcji przez badanie i 3 miesiące po jego zakończeniu
- •Zdolność do zrozumienia informacji o badaniu i podpisania świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Icahn School of Medicine at Mount Sinai
New York, United States
Trial contact
Lisa Fitzgerald
Rashmi Unawane
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.